|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Litronesib
|
MedKoo Code#: 205521
|
|
Name: Litronesib
|
|
CAS#: 910634-41-2
Synonym:
litronesib; Eg5 Kinesin-Related Motor Protein Inhibitor
LY2523355; Code name: LY2523355; KF 89617; Chemical
structure: Propanamide,
N-[4-(2,2-dimethyl-1-oxopropyl)-5-[[[[2-(ethylamino)ethyl]sulfonyl]
amino]methyl]-4,5-dihydro-5-phenyl-1,3,4-thiadiazol-2-yl]-2,2-dimethyl-,
(-)-
IUPAC/Chemical name:
(R)-N-(5-((2-(ethylamino)ethylsulfonamido)methyl)-5-phenyl-4-pivaloyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)pivalamide.
|
|
Chemical structure
|
Theoretical analysis
|
|
|
MedKoo Code#: 205521
Name: litronesib
CAS#: 910634-41-2
Chemical Formula: C23H37N5O4S2
Exact Mass: 511.22870
Molecular Weight: 511.70098
Elemental Analysis: C, 53.99; H, 7.29; N,
13.69; O, 12.51; S, 12.53
|
|
Availability and price:
This agent is
not in stock, may be available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
litronesib is an
inhibitor of the kinesin-related motor protein Eg5 with potential
antineoplastic activity. Litronesib selectively inhibits the activity of
Eg5, which may result in mitotic disruption, apoptosis and consequently
cell death in tumor cells that are actively dividing. The ATP-dependent
Eg5 kinesin-related motor protein (also known as KIF11 or kinesin
spindle protein-5) is a plus-end directed kinesin motor protein that
plays an essential role during mitosis, particularly in the regulation
of spindle dynamics, including assembly and maintenance. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
Current developer:
Eli Lilly.
1. Detection of circulating mRNA, microRNA, protein
and vesicle markers in disease diagnosis and selection of therapies By
Kuslich, Christine; Poste, George; Klass, Michael; Spetzler, David;
Pawlowski, Traci From PCT Int. Appl. (2011), WO 2011127219 A1 20111013.
2. Stable lyophilized and injectable formulations of thiadiazole
derivative By Kusano, Hiroko; Mishra, Dinesh Shyamdeo; Tashiro,
Yoshikazu; Watanabe, Yosuke; Zhuang, Hong From PCT Int. Appl. (2009), WO
2009009470 A1 20090115.
3. Preparation of thiadiazoline derivatives as therapeutic agents for
restenosis By Nakai, Ryuichiro; Shimoike, Emi; Kusaka, Hideaki; Murakata,
Chikara; Yamashita, Yoshinori From PCT Int. Appl. (2006), WO 2006137490
A1 20061228.
4. antiglaucoma agents containing thiadiazoline derivatives By Miki,
Ichiro; Nakai, Ryuichiro; Murakata, Isamu; Yamashita, Nobunori; Oshima,
Etsuo From Jpn. Kokai Tokkyo Koho (2006), JP 2006265107 A 20061005.
5. Preparation of thiadiazole derivatives for treatment of arthritis By
Miki, Ichiro; Uchii, Masako; Murakata, Chikara; Yamashita, Yoshinori;
Suda, Toshio From PCT Int. Appl. (2006), WO 2006101104 A1 20060928.
6. Preparation of thiadiazoline compounds for the treatment of solid
tumor By Murakata, Chikara; Kato, Kazuhiko; Yamamoto, Junichiro; Nakai,
Ryuichiro; Okamoto, Seiho; Ino, Yoji; Kitamura, Yushi; Saitoh,
Toshikazu; Katsuhira, Takeshi From PCT Int. Appl. (2006), WO 2006101102
A1 20060928.
7. Thiadiazoline derivatives for the treatment of psoriasis By Miki,
Ichiro; Uchii, Masako; Kobayashi, Katsuya; Harada, Daisuke From PCT Int.
Appl. (2006), WO 2006101105 A1 20060928.
8. Preparation of thiadiazoline derivatives for the treatment of
hematopoietic tumor By Nakai, Ryuichiro; Okamoto, Seiho; Kusaka,
Hideaki; Yamashita, Yoshinori; Ishida, Hiroyuki From PCT Int. Appl.
(2006), WO 2006101103 A1 20060928.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
